Glenmark Pharmaceuticals Ltd. India

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Glenmark Pharmaceuticals Ltd. India sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed later-stage tilt upper quartile by trial count

Glenmark Pharmaceuticals Ltd. India: 8 sponsored US clinical trials, none currently recruiting.

Glenmark Pharmaceuticals Ltd. India sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 7 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis, with 1 trials.

Upper-quartile sponsor footprint

Glenmark Pharmaceuticals Ltd. India sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 3

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).

NCT03731091
COMPLETED Phase 3

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
COMPLETED Phase 3

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
COMPLETED Phase 3

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

NCT02668796
COMPLETED Phase 3

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

NCT02596451
COMPLETED Phase 3

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

NCT02601703
COMPLETED Phase 3

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
COMPLETED Phase 2

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 7

Therapeutic Areas

Osteoarthritis 1

How the Glenmark Pharmaceuticals Ltd. India archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 7 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Osteoarthritis (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Glenmark Pharmaceuticals Ltd. India: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Glenmark Pharmaceuticals Ltd. India sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Glenmark Pharmaceuticals Ltd. IndiaAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Glenmark Pharmaceuticals Ltd. India sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Glenmark Pharmaceuticals Ltd. India sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Glenmark Pharmaceuticals Ltd. India page

8 registered trials is a research-attention snapshot, not an endorsement of Glenmark Pharmaceuticals Ltd. India or any single study.

  • None of Glenmark Pharmaceuticals Ltd. India's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Osteoarthritis is the condition Glenmark Pharmaceuticals Ltd. India studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteoarthritis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Glenmark Pharmaceuticals Ltd. India pipeline card: 8 registered trials from official public datasets.Report a data error.